Overview

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Status:
Recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

Phase I dose escalation clinical trial: to explore the dose limiting toxicity (DLT) of mitoxantrone hydrochloride liposome injection in the treatment of children with relapsed and refractory lymphoma and solid tumors. Pharmacokinetics clinical trial: to observe the pharmacokinetics of mitoxantrone hydrochloride liposomes in children with relapsed and refractory lymphoma and solid tumors. To evaluate the safety and efficacy of mitoxantrone hydrochloride liposomes in children with lymphoma and solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Mitoxantrone